Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biden Admin Pays Ellume $231M To Build COVID-19 US Test Plant

Executive Summary

The government seems to be betting the company’s over-the-counter at-home antigen diagnostic test will be a game changer in stopping the spread of the coronavirus.

You may also be interested in...



Top Republican Senators Criticize Biden Administration For Lack Of COVID-19 Tests

The top GOPers on the Senate health committee want to know what the administration has done with more than $80bn allocated by Congress to ramp up production of COVID-19 tests.

Developer Of First US OTC COVID-19 Antigen Test Plans 'Digital Diagnostics For Multitude Of Infectious Diseases'

The developer of the OTC at-home antigen test — the first of its kind to get an emergency use authorization from the FDA – received more than $200m from the US government to manufacture in the US. So what’s next for Ellume? In this Q&A, the Australian company’s CEO, Sean Parson, explains.

Ellume CEO Ponders Future Of Company’s Rapid COVID-19 Antigen Test

The developer of the at-home over-the-counter antigen test — the first of its kind to get an emergency use authorization from the FDA – received more than $200m from the government to manufacture in the US. So what’s next for Ellume? In this Medtech Insight case study Q&A, the Australian company’s CEO, Sean Parson, explains.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT143420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel